Detection and identification of potential biomarkers of breast cancer

Lung cancer is one of the most common cancers in terms of both incidence and mortality.The major reasons for the increasing number of deaths from lung cancer are late detection and lack of effective therapies. To improve our understanding of lung cancer biology, there is urgent need for blood-based, non-invasive molecular tests to assist in its detection in a cost-effective manner at an early stage when curative interventions are still possible. Recent advances in proteomic technology have provided extensive, high throughput analytical tools for identification, characterization and functional studies of proteomes. Changes in protein expression patterns in response to stimuli can serve as indicators or biomarkers of biological and pathological processes as well as physiological and pharmacological responses to drug treatment, thus aiding in early diagnosis and prognosis of disease. However, only a few biomarkers have been approved by the FDA to date for screening and diagnostic purposes. This review provides a brief overview of currently available proteomic techniques, their applications and limitations and the current state of knowledge about important serum biomarkers in lung cancer and their potential value as prognostic and diagnostic tools.

show abstract

“…Protein microarrays using multiple capture antibodies have also been used to detect and identify potential biomarkers for breast cancer [45].…”

Section: Technologies Involved In Proteomicsmentioning

confidence: 99%

Serum-based protein biomarkers for detection of lung cancer

2014

View full text Add to dashboard Cite

show abstract

“…Proteomics has been showed to be a promising method in breast cancer marker candidate (Fan et al 2010;Zheng et al 2010;Xu et al 2010). In recent years, as liquid chromatography and mass spectrometry methodologies have improved, interest in the proteomic analysis of human sera has increased Zolotarjova et al 2005;Freeman et al 2006).…”

Section: Introductionmentioning

confidence: 99%

Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach

Kadowaki

Sangai

Nagashima

et al. 2011

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Specific abnormalities of amino acid metabolism and levels have been reported in cancer, including breast cancer (Wise and Thompson, 2010;Nagata et al, 2014). The tumor's need for excessive consumption of amino acids for gaining energy (by carbohydrate and fat accumulation) results in a modification of amino acids concentration in blood (Fan et al, 2010(Fan et al, , 2012. Some studies have reported decreased concentrations of amino acids in biofluids, but others have reported increased concentrations, the turnover being related to the type of cancer and specific metabolic pathways (Lai et Gu et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

HPLC/MS-based Metabolic Profiling and Quantification of Urine Free Amino Acids as Potential Biomarkers for Breast Cancer Diagnosis and Progression

et al. 2015

View full text Add to dashboard Cite

Considering the key role of free amino acids in cell metabolism and their predictive role as biomarkers in breast cancer by alteration of their metabolic pathways, the purpose of this study was to identify and quantify the urine amino acids from healthy and breast cancer women, diagnosed in different histological stages. Using advanced LC-QTOF-(ESI+)-MS technique and EZ:faast kit, based on derivatization of free aminoacids, 16 amino acids from control and breast cancer groups, preliminarily classified in I-IIIA and II-IIIB stages were identified and quantified. The general LC/MS fingerprint showed significant quantitative differences, especially for serine, lysine, tyrosine and leucine and asparagine, which decreased or increased, respectively. The multivariate analysis (PCA) showed good discrimination between normal and pathological groups, with best discrimination by essential amino acids. Cluster Analysis confirmed three discrimination regions, a major BC group, the control-group and a minor five patient-group. When the mean values of essential and non-essential amino acids were represented, in relation to cancer stages, gradual decreases of non-essential and essential amino acids were observed, from stage I to IIIA and from II to IIIB, in a parallel manner, non-essential amino acids having 3.5 times higher values than essential amino acids, the decreases being more relevant for non-essential amino acids. Serine had the steepest decrease, followed by Tyrosine, both being recommended as good biomarker candidates. By ROC curves, lysine and isoleucine showed highest AUC values and confidence intervals to provide good diagnostic between healthy and BC groups. Nonetheless, in agreement with quantitative data and correlations with the breast cancer stages, serine and tyrosine had better potential to offer a good diagnosis and confidence in discriminating among different cancer progression stages.

show abstract

Detection and identification of potential biomarkers of breast cancer

Abstract: We have identified a set of biomarkers that could discriminate breast cancer from non-cancer controls. An efficient strategy, including SELDI-TOF-MS analysis, HPLC purification, MALDI-TOF-MS trace and LC-MS/MS identification, has been proved very successful.

Cited by 54 publications

References 24 publications

Serum-based protein biomarkers for detection of lung cancer

Serum-based protein biomarkers for detection of lung cancer

Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach

HPLC/MS-based Metabolic Profiling and Quantification of Urine Free Amino Acids as Potential Biomarkers for Breast Cancer Diagnosis and Progression

Contact Info

Product

Resources

About